Update on 2015 WHO Classification of Lung Adenocarcinoma [Hot Topic]


Anja Roden, M.D.

Most patients with lung cancer present at advanced stage and cannot be treated by surgical resection. Alternative treatment options are needed. Subtyping of lung cancer is very important because of advances in the identification of genetic abnormalities that allow for a more targeted approach in a subset of patients. Furthermore, some medications are contraindicated in certain lung cancer subtypes. In addition, lung cancer subtypes are of prognostic value. The 2015 WHO has a different approach to the diagnosis of lung adenocarcinoma and includes entities such as adenocarcinoma in situ and minimally invasive adenocarcinoma, while bronchoalveolar carcinoma was removed.

Because many patients with lung cancer are not surgical candidates, the biopsy specimen or cytology preparation will be the only specimen available for diagnosis and molecular testing in these patients. Therefore, tissue preservation is important. Furthermore, the 2015 WHO includes a new classification of small biopsies and cytology.

Presenters and Credentials:

Anja Roden, M.D., is an Associate Professor of Laboratory Medicine and Pathology, a Consultant in the Anatomic Pathology Laboratory, and Co-Director of the Immunostains Laboratory at Mayo Clinic in Rochester, Minnesota.


MML Education

This post was developed by our Education and Technical Publications Team.